Novelix Pharma Secures Capital Via Warrant Conversion, Director Steps Down

Novelix Pharmaceuticals has secured ₹1.73 crore through the conversion of warrants, a move that boosts its paid-up equity capital by ₹1.15 crore. The company's board also accepted the resignation of Non-Executive Director Mr. Jivamohan Divakar Valluri.

Capital Boost from Warrant Conversion

On March 30, 2026, Novelix Pharmaceuticals' Board of Directors approved the allotment of 1,150,000 equity shares. These shares were issued at an aggregate price of ₹2.30 crore, with ₹1.73 crore received from the conversion of warrants, representing 75% of the issue price. The face value of these shares adds ₹1.15 crore to the company's paid-up equity capital, strengthening its financial base.

Director Resignation

Simultaneously with the capital allotment, the board accepted the resignation of Mr. Jivamohan Divakar Valluri from his position as Non-Executive Director, effective March 30, 2026. This change alters the company's board composition.

Why the Capital Injection Matters

This capital infusion from warrant conversion provides Novelix Pharmaceuticals with crucial funds. The money can support ongoing operations, research initiatives, and working capital needs. This is particularly timely given the company's strategic pivot into pharmaceutical research and bulk drug manufacturing.

The departure of a director, particularly a non-executive one, can sometimes signal shifts in strategic direction or governance oversight. Investors will watch for any developments or succession plans.

Company Background and Strategy

Novelix Pharmaceuticals, previously known as Trimurti Limited, has been actively raising capital through mechanisms like preferential issues and warrant conversions. This strategy supports its evolving business objectives, especially following its name change to Novelix Pharmaceuticals in October 2024. The company has signaled a pivot towards pharmaceutical research, bulk drugs, and healthcare technology. Recent capital raises include ₹13.92 crore in February 2026 via a preferential issue, and prior warrant conversions in January 2026 and October 2025.

The current capital raise fits the company's strategy of deleveraging or funding growth through equity. The total equity base expands, which may impact financial ratios.

Risks and Challenges

Despite recent positive quarterly results, Novelix Pharmaceuticals faces challenges. MarketsMojo rates the stock a 'Hold,' citing an average quality grade. The company shows a modest Return on Equity (ROE) of 0.76% and a poor EBIT to Interest ratio of -0.83, suggesting potential difficulties in servicing debt. Historically, Novelix has shown low ROE (0.64% over three years) and high debtors (216 days). Past net losses, such as in the June 2024 quarter, highlight the ongoing need for financial strengthening. The director's resignation adds another point for governance observation.

Peer Landscape in Pharma

Novelix Pharmaceuticals operates in the Indian pharmaceutical sector. It is among peers like Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Lupin Ltd., and Dr. Reddy's Laboratories Ltd. These larger companies typically have more diversified revenue streams and stronger financial foundations, underscoring the importance of Novelix's capital-raising activities for its growth trajectory.